Restricted accessResearch articleFirst published online 2015-09
Inhibition of NADPH Oxidase-4 Potentiates 2-Deoxy- d -Glucose-Induced Suppression of Glycolysis,Migration,and Invasion in Glioblastoma Cells: Role of the Akt/HIF1α/HK-2 Signaling Axis
Aims: 2-Deoxy-d-glucose (2-DG), a synthetic glycolytic inhibitor, is currently under clinical evaluation as a promising anticancer agent. However, 2-DG treatment in cancer cells activates prosurvival Akt signaling that might limit its clinical efficacy. The NADPH oxidase 4 (Nox-4)/reactive oxygen species/Akt signaling is known to regulate survival, proliferation, infiltration, and invasion in glioblastomas (GBMs). The enhanced motility, invasiveness, and therapy resistance in GBMs are attributed to metabolic adaptation through increased aerobic glycolysis. Therefore, we hypothesized that inhibition of the Nox-4 might enhance 2-DG-induced suppression of glycolysis, migration, and invasion in GBM cells. Results: We identified the natural naphthoquinone compound shikonin as a potent inhibitor of the Nox-4/Akt signaling pathway. The combined treatment of shikonin+2-DG suppressed the glycolytic phenotype, migration, and invasion through modulation of the Akt/HIF1α/hexokinase-2 signaling axis in GBM cells. The combination also exhibited enhanced antiproliferative and antiangiogenic effects in vivo.Innovation: Our data for the first time demonstrate that inhibition of the Nox-4-associated prosurvival signaling pathway by shikonin enhances the antiproliferative and antiangiogenic potential of 2-DG in GBM cells. Conclusion: In summary, the combined inhibition of Nox-4 and glycolysis may have therapeutic implications for the management of GBMs. Antioxid. Redox Signal. 23, 665–681.
Get full access to this article
View all access options for this article.
References
1.
AftRL, ZhangFW, and GiusD. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer, 87: 805–812, 2002.
2.
AhnJ, WonM, ChoiJH, KimYS, JungCR, ImDS, KyunML, LeeK, SongKB, and ChungKS. Reactive oxygen species-mediated activation of the Akt/ASK1/p38 signaling cascade and p21(Cip1) downregulation are required for shikonin-induced apoptosis. Apoptosis, 18: 870–881, 2013.
3.
AmbastaRK, KumarP, GriendlingKK, SchmidtHH, BusseR, and BrandesRP. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem, 279: 45935–45941, 2004.
4.
AtkinsRJ, DimouJ, ParadisoL, MorokoffAP, KayeAH, DrummondKJ, and HovensCM. Regulation of glycogen synthase kinase-3 beta (GSK-3beta) by the Akt pathway in gliomas. J Clin Neurosci, 19: 1558–1563, 2012.
5.
BasantaD, SimonM, HatzikirouH, and DeutschA. Evolutionary game theory elucidates the role of glycolysis in glioma progression and invasion. Cell Prolif, 41: 980–987, 2008.
6.
BaumannF, LeukelP, DoerfeltA, BeierCP, DettmerK, OefnerPJ, KastenbergerM, KreutzM, Nickl-JockschatT, BogdahnU, BosserhoffAK, and HauP. Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro Oncol, 11: 368–380, 2009.
7.
BecknerME, GobbelGT, AbounaderR, BurovicF, AgostinoNR, LaterraJ, and PollackIF. Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Lab Invest, 85: 1457–1470, 2005.
8.
Ben-SahraI, DiratB, LaurentK, PuissantA, AubergerP, BudanovA, TantiJF, and BostF. Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death. Cell Death Differ, 20: 611–619, 2013.
9.
Bobrovnikova-MarjonEV, MarjonPL, BarbashO, Vander JagtDL, and AbcouwerSF. Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-kappaB and activating protein-1. Cancer Res, 64: 4858–4869, 2004.
10.
ChenCH, LinML, OngPL, and YangJT. Novel multiple apoptotic mechanism of shikonin in human glioma cells. Ann Surg Oncol, 19: 3097–3106, 2012.
11.
ChenJ, XieJ, JiangZ, WangB, WangY, and HuX. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene, 30: 4297–4306, 2011.
12.
ChenJS, HuangXH, WangQ, HuangJQ, ZhangLJ, ChenXL, LeiJ, and ChengZX. Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer. Carcinogenesis, 34: 10–19, 2013.
13.
ChiangE, DangO, AndersonK, MatsuzawaA, IchijoH, and DavidM. Cutting edge: apoptosis-regulating signal kinase 1 is required for reactive oxygen species-mediated activation of IFN regulatory factor 3 by lipopolysaccharide. J Immunol, 176: 5720–5724, 2006.
14.
ColenCB, ShenY, GhoddoussiF, YuP, FrancisTB, KochBJ, MontereyMD, GallowayMP, SloanAE, and MathupalaSP. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia, 13: 620–632, 2011.
15.
DeSalvoJ, KuznetsovJN, DuJ, LeclercGM, LeclercGJ, LampidisTJ, and BarredoJC. Inhibition of Akt potentiates 2-DG-induced apoptosis via downregulation of UPR in acute lymphoblastic leukemia. Mol Cancer Res, 10: 969–978, 2012.
16.
DingY, ChenZJ, LiuS, CheD, VetterM, and ChangCH. Inhibition of Nox-4 activity by plumbagin, a plant-derived bioactive naphthoquinone. J Pharm Pharmacol, 57: 111–116, 2005.
17.
DwarakanathBS, SinghD, BanerjiAK, SarinR, VenkataramanaNK, JalaliR, VishwanathPN, MohantiBK, TripathiRP, KaliaVK, and JainV. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J Cancer Res Ther, 5Suppl 1: S21–S26, 2009.
18.
EglerV, KorurS, FaillyM, BoulayJL, ImberR, LinoMM, and MerloA. Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clin Cancer Res, 14: 3132–3140, 2008.
19.
El SayedSM, Abou El-MagdRM, ShishidoY, ChungSP, SakaiT, WatanabeH, KagamiS, and FukuiK. D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate. Cancer Gene Ther, 19: 1–18, 2012.
20.
ElstromRL, BauerDE, BuzzaiM, KarnauskasR, HarrisMH, PlasDR, ZhuangH, CinalliRM, AlaviA, RudinCM, and ThompsonCB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res, 64: 3892–3899, 2004.
21.
EstanMC, CalvinoE, de BlasE, Boyano-Adanez MdelC, MenaML, Gomez-GomezM, RialE, and AllerP. 2-Deoxy-d-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways. Biochem Pharmacol, 84: 1604–1616, 2012.
22.
GatenbyRA and GawlinskiET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res, 63: 3847–3854, 2003.
23.
GongK and LiW. Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: a potential new treatment for hepatocellular carcinoma. Free Radic Biol Med, 51: 2259–2271, 2011.
24.
GottlobK, MajewskiN, KennedyS, KandelE, RobeyRB, and HayN. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev, 15: 1406–1418, 2001.
25.
GriguerCE and OlivaCR. Bioenergetics pathways and therapeutic resistance in gliomas: emerging role of mitochondria. Curr Pharm Des, 17: 2421–2427, 2011.
26.
HeerdtBG, HoustonMA, and AugenlichtLH. The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression. Cancer Res, 65: 9861–9867, 2005.
27.
HeerdtBG, HoustonMA, and AugenlichtLH. Growth properties of colonic tumor cells are a function of the intrinsic mitochondrial membrane potential. Cancer Res, 66: 1591–1596, 2006.
28.
IchijoH, NishidaE, IrieK, ten DijkeP, SaitohM, MoriguchiT, TakagiM, MatsumotoK, MiyazonoK, and GotohY. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science, 275: 90–94, 1997.
29.
JoshiS, SinghAR, ZulcicM, and DurdenDL. A macrophage dominant PI-3K isoform controls hypoxia induced HIF1alpha and HIF2alpha stability and tumor growth, angiogenesis and metastasis. Mol Cancer Res, 12: 1520–1531, 2014.
30.
KatoY, LambertCA, ColigeAC, MineurP, NoelA, FrankenneF, FoidartJM, BabaM, HataR, MiyazakiK, and TsukudaM. Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase D-mitogen-activated protein kinase signaling. J Biol Chem, 280: 10938–10944, 2005.
31.
KavithaCV, AgarwalC, AgarwalR, and DeepG. Asiatic acid inhibits pro-angiogenic effects of VEGF and human gliomas in endothelial cell culture models. PLoS One, 6: e22745, 2011.
32.
KeLD, ShiYX, ImSA, ChenX, and YungWK. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clin Cancer Res, 6: 2562–2572, 2000.
33.
KeunenO, JohanssonM, OudinA, SanzeyM, RahimSA, FackF, ThorsenF, TaxtT, BartosM, JirikR, MileticH, WangJ, StieberD, StuhrL, MoenI, RyghCB, BjerkvigR, and NiclouSP. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A, 108: 3749–3754, 2011.
KrutzfeldtA, SpahrR, MertensS, SiegmundB, and PiperHM. Metabolism of exogenous substrates by coronary endothelial cells in culture. J Mol Cell Cardiol, 22: 1393–1404, 1990.
36.
KwonJ, LeeSR, YangKS, AhnY, KimYJ, StadtmanER, and RheeSG. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A, 101: 16419–16424, 2004.
37.
LeeBL, KimWH, JungJ, ChoSJ, ParkJW, KimJ, ChungHY, ChangMS, and NamSY. A hypoxia-independent up-regulation of hypoxia-inducible factor-1 by AKT contributes to angiogenesis in human gastric cancer. Carcinogenesis, 29: 44–51, 2008.
38.
LeeHJ, LeeHJ, MageshV, NamD, LeeEO, AhnKS, JungMH, AhnKS, KimDK, KimJY, and KimSH. Shikonin, acetylshikonin, and isobutyroylshikonin inhibit VEGF-induced angiogenesis and suppress tumor growth in lewis lung carcinoma-bearing mice. Yakugaku Zasshi, 128: 1681–1688, 2008.
39.
LuW, HuY, ChenG, ChenZ, ZhangH, WangF, FengL, PelicanoH, WangH, KeatingMJ, LiuJ, McKeehanW, WangH, LuoY, and HuangP. Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol, 10: e1001326, 2012.
40.
MaherJC, WangpaichitrM, SavarajN, KurtogluM, and LampidisTJ. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-d-glucose. Mol Cancer Ther, 6: 732–741, 2007.
41.
MaoH, LebrunDG, YangJ, ZhuVF, and LiM. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest, 30: 48–56, 2012.
42.
MaraldiT. Natural compounds as modulators of NADPH oxidases. Oxid Med Cell Longev, 2013: 271602, 2013.
43.
MaschekG, SavarajN, PriebeW, BraunschweigerP, HamiltonK, TidmarshGF, De YoungLR, and LampidisTJ. 2-Deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res, 64: 31–34, 2004.
44.
MathupalaSP, RempelA, and PedersenPL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem, 276: 43407–43412, 2001.
45.
MerchanJR, KovacsK, RailsbackJW, KurtogluM, JingY, PinaY, GaoN, MurrayTG, LehrmanMA, and LampidisTJ. Antiangiogenic activity of 2-deoxy-d-glucose. PLoS One, 5: e13699, 2010.
46.
MichelakisED, SutendraG, DromparisP, WebsterL, HaromyA, NivenE, MaguireC, GammerTL, MackeyJR, FultonD, AbdulkarimB, McMurtryMS, and PetrukKC. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med, 2: 31ra34, 2010.
47.
MondolAS, TonksNK, and KamataT. Nox4 redox regulation of PTP1B contributes to the proliferation and migration of glioblastoma cells by modulating tyrosine phosphorylation of coronin-1C. Free Radic Biol Med, 67: 285–291, 2014.
48.
NepalM, ChoiHJ, ChoiBY, KimSL, RyuJH, Kim DoH, LeeYH, and SohY. Anti-angiogenic and anti-tumor activity of Bavachinin by targeting hypoxia-inducible factor-1alpha. Eur J Pharmacol, 691: 28–37, 2012.
49.
PalmieriD, FitzgeraldD, ShreeveSM, HuaE, BronderJL, WeilRJ, DavisS, StarkAM, MerinoMJ, KurekR, MehdornHM, DavisG, SteinbergSM, MeltzerPS, AldapeK, and SteegPS. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res, 7: 1438–1445, 2009.
50.
RobeyRB and HayN. Akt, hexokinase, mTOR: targeting cellular energy metabolism for cancer therapy. Drug Discov Today Dis Mech, 2: 239–246, 2005.
51.
SchmidtM, VoelkerHU, KappM, KrockenbergerM, DietlJ, and KammererU. Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol, 136: 219–225, 2010.
52.
SemenzaGL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3: 721–732, 2003.
53.
ShonoT, YokoyamaN, UesakaT, KurodaJ, TakeyaR, YamasakiT, AmanoT, MizoguchiM, SuzukiSO, NiiroH, MiyamotoK, AkashiK, IwakiT, SumimotoH, and SasakiT. Enhanced expression of NADPH oxidase Nox4 in human gliomas and its roles in cell proliferation and survival. Int J Cancer, 123: 787–792, 2008.
54.
SottnikJL, LoriJC, RoseBJ, and ThammDH. Glycolysis inhibition by 2-deoxy-d-glucose reverts the metastatic phenotype in vitro and in vivo. Clin Exp Metastasis, 28: 865–875, 2011.
55.
SrivastavaVK, GaraRK, BhattML, SahuDP, and MishraDP. Centchroman inhibits proliferation of head and neck cancer cells through the modulation of PI3K/mTOR pathway. Biochem Biophys Res Commun, 404: 40–45, 2011.
56.
SunQ, ChenX, MaJ, PengH, WangF, ZhaX, WangY, JingY, YangH, ChenR, ChangL, ZhangY, GotoJ, OndaH, ChenT, WangMR, LuY, YouH, KwiatkowskiD, and ZhangH. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A, 108: 4129–4134, 2011.
57.
TorresS, LorenteM, Rodriguez-FornesF, Hernandez-TiedraS, SalazarM, Garcia-TaboadaE, BarciaJ, GuzmanM, and VelascoG. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther, 10: 90–103, 2011.
58.
TsurutaniJ, FukuokaJ, TsurutaniH, ShihJH, HewittSM, TravisWD, JenJ, and DennisPA. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol, 24: 306–314, 2006.
59.
UhmJH, DooleyNP, VillemureJG, and YongVW. Mechanisms of glioma invasion: role of matrix-metalloproteinases. Can J Neurol Sci, 24: 3–15, 1997.
60.
WangW, DaiM, ZhuC, ZhangJ, LinL, DingJ, and DuanW. Synthesis and biological activity of novel shikonin analogues. Bioorg Med Chem Lett, 19: 735–737, 2009.
61.
WangpaichitrM, SavarajN, MaherJ, KurtogluM, and LampidisTJ. Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-d-glucose under hypoxia in lung cancer cell lines. Mol Cancer Ther, 7: 1506–1513, 2008.
62.
WolfA, AgnihotriS, MicallefJ, MukherjeeJ, SabhaN, CairnsR, HawkinsC, and GuhaA. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med, 208: 313–326, 2011.
WongML, KayeAH, and HovensCM. Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci, 14: 301–308, 2007.
65.
WuH, ZhuH, LiuDX, NiuTK, RenX, PatelR, HaitWN, and YangJM. Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-d-glucose against human glioma cells through blunting of autophagy. Cancer Res, 69: 2453–2460, 2009.
66.
YangJT, LiZL, WuJY, LuFJ, and ChenCH. An oxidative stress mechanism of shikonin in human glioma cells. PLoS One, 9: e94180, 2014.
67.
ZhangC, LanT, HouJ, LiJ, FangR, YangZ, ZhangM, LiuJ, and LiuB. NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K/Akt signaling. Oncotarget, 5: 4392–4405, 2014.
68.
ZhongD, LiuX, Schafer-HalesK, MarcusAI, KhuriFR, SunSY, and ZhouW. 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther, 7: 809–817, 2008.
69.
ZhongD, XiongL, LiuT, LiuX, LiuX, ChenJ, SunSY, KhuriFR, ZongY, ZhouQ, and ZhouW. The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem, 284: 23225–23233, 2009.
70.
ZhongH, ChilesK, FeldserD, LaughnerE, HanrahanC, GeorgescuMM, SimonsJW, and SemenzaGL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res, 60: 1541–1545, 2000.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
